2. Intolerance to sorafenib consisting of CTCAE grade 2 or greater drug-related AE which persisted in spite of comprehensive supportive therapy according to institutional standards AND persisted or recurred after sorafenib treatment interruption of at least 7 days and dose reduction by one dose level (to 400 mg once daily).